There are at least five kinds of NE receptors (two alpha subtypes and three beta subtypes). Which one of them do you want to block?
Drugs like clonidine decrease NE activity by acting as agonists in the presynaptic alpha2 receptors that inhibit NE release.
From literature I've read, I am assuming Alpha blocker would be the more viable of the two, as beta without it is frequently cited as dangerous in such cases.
My question is firstly whether there are selective blockers for NA over other monoamines in currency with good efficacy, used in the medical &/or academic RC capacity, regardless of sub-type specificity, as dopamine-drug potentiators (as unselective as possible seems safest)? Is this truly viable with alpha &/or beta blockers? It is only a secondary consideration about which sub-types are easier to single out for this effect and which may be the best for dopamine's euphorigenic potentiation. Theoretically of course, as there is not to my knowledge a pool of practical application for much of a concrete basis on such experiences used in large amounts with DAT uptake inhibitors. (though if extant, would be just as fascinating related here in this regard)
Would there, for instance, be a safe ratio at which a DRI was also an alpha or beta blocker due to, as far as I know, NE also being transported when in large amounts by DAT which may off-set or mediate the effect of NE. From what I understand, an unselective as possible NE antagonist (alpha & beta) would be safest; if a drug were a certain affinity for DAT, it could be a certain affinity as an unselective NE antagonist that may be purely euphorigenic?
Perhaps NE release blockers are a better candidate? (e.g. Bethanidine, Bretylium, Guanadrel) Would their effects be mutually exclusive with monoamine reuptake inhibiting ligands on a transporter by transporter basis if occupied with a DRI?